Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone...

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C514S399000, C548S311400, C548S465000, C548S408000

Reexamination Certificate

active

07053114

ABSTRACT:
The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.

REFERENCES:
patent: 5792783 (1998-08-01), Tang et al.
patent: 6395734 (2002-05-01), Tang et al.
patent: 6482848 (2002-11-01), Moon et al.
patent: 6797725 (2004-09-01), Sun et al.
patent: WO 90/08128 (1990-07-01), None
patent: WO 99/61422 (1999-12-01), None
patent: WO 00/08202 (2000-02-01), None
patent: WO 01/90103 (2001-11-01), None
Monse et al. 2004, CAS:141:38635.
Bundgaard, “Design of Prodrugs: Bioreversible dervatives for various functional groups and chemical entities,”Design of Prodrugs, Chapter 1, 1985, pp. 10-27.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3639233

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.